110 related articles for article (PubMed ID: 17959551)
1. [About the infrequent thrombotic events during erythropoietin therapy of anemia in ovarian cancer patients treated with chemotherapy].
Lehoczky O; Pulay T
Orv Hetil; 2007 Nov; 148(44):2081-5. PubMed ID: 17959551
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
3. Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer.
Westin SN; Skinner EN; Jonsson Funk M; Gehrig PM; Van Le L
Gynecol Oncol; 2007 May; 105(2):414-7. PubMed ID: 17250880
[TBL] [Abstract][Full Text] [Related]
4. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
[TBL] [Abstract][Full Text] [Related]
5. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
6. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
7. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
[TBL] [Abstract][Full Text] [Related]
8. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
[TBL] [Abstract][Full Text] [Related]
9. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
[TBL] [Abstract][Full Text] [Related]
10. Utilisation review of epoetin alfa in cancer patients at a cancer centre in Singapore.
Chan A; Lim LL; Tao M
Singapore Med J; 2009 Apr; 50(4):365-70. PubMed ID: 19421679
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
[TBL] [Abstract][Full Text] [Related]
12. Darbepoetin alfa: potential role in managing anemia in cancer patients.
Pirker R; Smith R
Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
Welch RS; James RD; Wilkinson PM; Belli F; Cowan RA
Cancer J Sci Am; 1995; 1(4):261-6. PubMed ID: 9166486
[TBL] [Abstract][Full Text] [Related]
14. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
Glaspy JA; Tchekmedyian NS
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):23-9. PubMed ID: 12435170
[TBL] [Abstract][Full Text] [Related]
17. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
Yang MC
Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
[No Abstract] [Full Text] [Related]
18. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
[TBL] [Abstract][Full Text] [Related]
19. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy.
Demetri GD; Gabrilove JL; Blasi MV; Hill RJ; Glaspy J
Clin Breast Cancer; 2002 Apr; 3(1):45-51. PubMed ID: 12020395
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
Boccia R; Lillie T; Tomita D; Balducci L
Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
